Marilyn Jean Manco-Johnson

Marilyn Jean Manco-Johnson

Auto-generated profile, based on publicly available information

Marilyn Jean Manco-Johnson

Hemophilia and Thrombosis Center, University of Colorado Anschutz Medical Campus, Aurora, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2013 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
MMM. J. Manco‐Johnson
M. J. Manco‐Johnson
CKC. L. Kempton
C. L. Kempton
MRM. T. Reding
M. T. Reding
TLT. Lissitchkov
T. Lissitchkov
SGS. Goranov
S. Goranov
WHW. Hong
W. Hong
Background The benefits of routine prophylaxis vs. on‐demand treatment with factor VIII products have not been evaluated in controlled clinical trials in older patients with hemophilia A. Objectives To report results from a preplanned analysis of data from the first year of the 3‐year SPINART study, which compares routine prophylaxis with on‐demand treatment with sucrose‐formulated recombinant FVIII (rFVIII‐FS). Patients/Methods SPINART is an open‐label, randomized, controlled, parallel‐group, multinational trial. Males aged 12–50 years with severe hemophilia A, ≥ 150 days of exposure to FVIII, no FVIII inhibitors, no prophylaxis for > 12 consecutive months in the past 5 years and 6–24 bleeding episodes in the preceding 6 months were randomized 1 : 1 to rFVIII‐FS prophylaxis (25 IU kg−1, three times weekly) or on‐demand treatment. The primary efficacy endpoint, number of total bleeding episodes in the intent‐to‐treat population, was analyzed after the last patient had completed 1 year of follow‐up. A negative binomial model was used for the primary endpoint analysis; analysis of variance was used for confirmatory analysis of annualized bleeding rates. Results Eighty‐four patients were enrolled and analyzed (n = 42 per group; mean age, 30.6 years; median treatment duration, 1.7 years). The median number of total bleeding episodes and total bleeding episodes per year were significantly lower with prophylaxis than with on‐demand treatment (total, 0 vs. 54.5; total per year, 0 vs. 27.9; both P < 0.0001). No treatment‐related adverse events occurred, and no patients developed FVIII inhibitors. Conclusions Routine prophylaxis with rFVIII‐FS leads to a significant reduction in bleeding as compared with on‐demand treatment. Adverse events were consistent with the established rFVIII‐FS safety profile.

26 March 2022 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
JSJean St‐Louis
Jean St‐Louis
AAAudrey Abad
Audrey Abad
SFSharon Funk
Sharon Funk
MTMerlyn Tilak
Merlyn Tilak
SCStephen Classey
Stephen Classey
BFBrian Michael Feldman
Brian Michael Feldman
The Hemophilia Joint Health Score (HJHS) was developed and validated to detect arthropathy in children. Additional evidence is required to show validity in adults. We studied the convergent and discriminant construct validity of the HJHS version 2.1(HJHSv2.1) in adults with hemophilia. A secondary aim was to define age‐related normative adult HJHSv2.1 reference values. We studied 192 adults with hemophilia, and 120 healthy adults in four age‐matched groups—18 to 29, 30 to 40, 41 to 50, and >50 years—at nine centers. Trained physiotherapists scored the HJHS and World Federation of Hemophilia (WFH) joint score. Health history, the Functional Independence Scale of Hemophilia (FISH), Hemophilia Activities List (HAL), and Short‐Form McGill Pain Questionnaire (SF‐MPQ) were also collected. The median age was 35.0 years. Of participants with hemophilia, 68% had severe, 14% moderate, and 18% mild disease. The HJHS correlated strongly with WFH score (Spearman’s rho [rs ] = .95, P < .001). Moderate correlations were seen between the FISH (rs = .50, P < .001) and SF‐MPQ Present Pain Intensity (rs = .50, P < .001), while a modest correlation was found with the HAL (rs = −.37, P < .001). The HJHS significantly differentiated between age groups (Kruskal‐Wallis T = 35.02, P < .001) and disease severity in participants with hemophilia. The HJHS had high internal reliability (Cronbach’s α = .88). We identified duration of swelling as a redundant item in the HJHS. The HJHS shows evidence of strong convergent and discriminant construct validity to detect arthropathy in adults with hemophilia and is well suited for use in this population.

3 June 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
BWBeth Boulden Warren
Beth Boulden Warren
DTDianne Thornhill
Dianne Thornhill
JSJill Stein
Jill Stein
MFMichael Fadell
Michael Fadell
JIJ. David Ingram
J. David Ingram
MMMarilyn J. Manco-Johnson
Marilyn J. Manco-Johnson
The Joint Outcome Study (JOS), a randomized controlled trial, demonstrated that children with severe hemophilia A (HA) initiating prophylactic factor VIII (FVIII) prior to age 2.5 years had reduced joint damage at age 6 years compared with those treated with episodic FVIII for bleeding. The Joint Outcome Continuation Study (JOS-C) evaluated early vs delayed prophylaxis effects on long-term joint health, following JOS participants to age 18 years in an observational, partially retrospective study. Index joint magnetic resonance imaging (MRI) scores of osteochondral (OC) damage (primary outcome), joint physical examination scores, and annualized rates of joint/other bleeding episodes (secondary outcomes) were collected. Thirty-seven of 65 JOS participants enrolled in JOS-C, including 15 randomized to prophylaxis at mean age 1.3 years (“early prophylaxis”); 18 initially randomized to episodic treatment, starting “delayed prophylaxis” at mean age 7.5 years; and 4 with high-titer inhibitors. At JOS-C exit, MRI OC damage was found in 77% of those on delayed and 35% of those on early prophylaxis for an odds ratio of OC damage, in the delayed vs early prophylaxis group, of 6.3 (95% confidence interval, 1.3, 29.9; P = .02). Annualized bleeding rates were higher with delayed prophylaxis (mean plus or minus standard deviation, 10.6 ± 6.6 vs 3.5 ± 2.1; P < .001), including when only comparing time periods on prophylaxis (6.2 ± 5.3 vs 3.3 ± 1.9; P < .05). In severe HA, early initiation of prophylaxis provided continued protection against joint damage throughout childhood compared with delayed initiation, but early prophylaxis was not sufficient to fully prevent damage. This trial was registered at www.clinicaltrials.gov as #NCT01000844.

24 August 2017 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
MMM. J. Manco‐Johnson
M. J. Manco‐Johnson
BLB. Lundin
B. Lundin
SFS. Funk
S. Funk
CPC. Peterfy
C. Peterfy
DRD. Raunig
D. Raunig
WHW. Hong
W. Hong
Essentials High‐quality data are lacking on use of prophylaxis in adults with hemophilia and arthropathy. SPINART was a 3‐year randomized clinical trial of late/tertiary prophylaxis vs on‐demand therapy. Prophylaxis improved function, quality of life, activity and pain but not joint structure by MRI. Prophylaxis improves function but must start before joint bleeding onset to prevent arthropathy. Summary Background Limited data exist on the impact of prophylaxis on adults with severe hemophilia A and pre‐existing joint disease. Objectives To describe 3‐year bleeding, joint health and structure, health‐related quality‐of‐life (HRQoL) and other outcomes from the open‐label, randomized, multinational SPINART study. Patients/Methods Males aged 12–50 years with severe hemophilia A, ≥ 150 factor VIII exposure days, no inhibitors and no prophylaxis for > 12 consecutive months in the past 5 years were randomized to sucrose‐formulated recombinant FVIII prophylaxis or on‐demand therapy (OD). Data collected included total and joint bleeding events (BEs), joint structure (magnetic resonance imaging [MRI]), joint health (Colorado Adult Joint Assessment Scale [CAJAS]), HRQoL, pain, healthcare resource utilization (HRU), activity, and treatment satisfaction. Results Following 3 years of prophylaxis, adults maintained excellent adherence, with a 94% reduction in BEs despite severe pre‐existing arthropathy; 35.7% and 76.2% of prophylaxis participants were bleed‐free or had fewer than two BEs per year, respectively. As compared with OD, prophylaxis was associated with improved CAJAS scores (least squares [LS] mean, − 0.31 [n = 42] versus + 0.63 [n = 42]) and HAEMO‐QoL‐A scores (LS mean, + 3.98 [n = 41] versus − 6.00 [n = 42]), less chronic pain (50% decrease), and approximately two‐fold less HRU; activity, Euro QoL‐5D‐3L (EQ‐5D‐3L) scores and satisfaction scores also favored prophylaxis. However, MRI score changes were not different for prophylaxis versus OD (LS mean, + 0.79 [n = 41] versus + 0.96 [n = 38]). Conclusions Over a period of 3 years, prophylaxis versus OD in adults with severe hemophilia A and arthropathy led to decreased bleeding, pain, and HRU, better joint health, activity, satisfaction, and HRQoL, but no reduction in structural arthropathy progression, suggesting that pre‐existing joint arthropathy may be irreversible.

23 November 2009 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
MMM. J. Manco‐Johnson
M. J. Manco‐Johnson
DDD. Dimichele
D. Dimichele
GCG. Castaman
G. Castaman
SFS. Fremann
S. Fremann
SKS. Knaub
S. Knaub
FGFOR THE FIBRINOGEN CONCENTRATE STUDY GROUP
FOR THE FIBRINOGEN CONCENTRATE STUDY GROUP
Summary. Background: Although fibrinogen concentrate has been available for the treatment of congenital fibrinogen deficiency for years, knowledge of its pharmacokinetics comes from only two small studies. Objectives: To assess the pharmacokinetic (PK) profile, clot integrity and safety of fibrinogen concentrate (human) (FCH) in patients with afibrinogenemia. Patients and methods: A multinational, prospective, open‐label, uncontrolled study of patients with afibrinogenemia ≥ 6 years of age was conducted in the USA and Italy. Plasma was collected before and after infusion for PK analyses and evaluation by rotational thromboelastometry of maximum clot firmness (MCF) to assess clot integrity. Safety was assessed on the basis of adverse events and laboratory parameters. Results: After a single dose of 70 mg kg−1 body weight (b.w.) FCH in 14 patients, median incremental in vivo recovery was a 1.7 mg dL−1 increase per mg kg−1 b.w., and median levels were 1.3 g L−1 for fibrinogen activity and antigen 1 h after infusion. Median half‐life (t1/2) was 77.1 h for fibrinogen activity and 88.0 h for antigen. Plasma recovery in children < 16 years old was similar to that in adults aged 16 to < 65 years, but the t1/2 and area under the curve were decreased, with an increased steady‐state volume and clearance. MCF increased by a mean of 8.9 mm from baseline to 1 h after infusion of FCH (P < 0.0001). All four adverse events reported were mild, and none was serious or related to study drug. Conclusions: These PK findings confirm a rapid increase in plasma fibrinogen levels after infusion with FCH. Together with the clot integrity and safety data and published data on efficacy, the results support the idea that FCH substitution can restore hemostasis with a good safety profile.

4 January 2021 in Haemophilia
Verified
Journal Article
Closed access
PDF file
MMMarilyn J. Manco‐Johnson
Marilyn J. Manco‐Johnson
BWBeth Boulden Warren
Beth Boulden Warren
TBTyler W. Buckner
Tyler W. Buckner
SFSharon M. Funk
Sharon M. Funk
MWMichael Wang
Michael Wang